SynAct Pharma AB is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation.
Our lead asset AP1189 is being evaluated in three Phase 2 clinical programs: rheumatoid arthritis (RA), and idiopathic membranous nephropathy (iMN, a form of nephrotic syndrome).
Our lead asset AP1189 is being evaluated in three Phase 2 clinical programs: rheumatoid arthritis (RA), and idiopathic membranous nephropathy (iMN, a form of nephrotic syndrome).
Ticker:
SYNACT
Exchange:
Nasdaq Stockholm
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
NA
Company HQ Country:
Sweden
Year Founded:
2012
Main Therapeutic Focus:
Inflammation
Lead Product in Development:
AP1189
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
